Mepsevii is an enzyme replacement therapy for patients with Mucopolysaccharidosis VII, an inherited metabolic condition. The disease is extremely rare, affecting an estimated 200 patients globally.
“Prior to today’s approval, patients with this rare, inherited condition had no approved treatment options,” said Julie Beitz, MD, director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research.
Ultragenyx expects Mepsevii to hit the market later this month.
More articles on supply chain:
Prime Healthcare taps HealthTrust for GPO services
Acorda Therapeutics halts Parkinson’s drug trials after 5 patient deaths
Cardinal Health to sell Chinese distribution business to Shanghai Pharma
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.